secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2024-06-07T23:59:59+00:00
Accession:  0001193125-24-157311
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir stockholders elect three Class I directors and ratify Deloitte as auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Elected Juan Vera (77.7M for, 4.2M withhold), Morana Jovan-Embiricos (76.2M for, 5.8M withhold), Derek Adams (76.2M for, 5.7M withhold) as Class I directors.
- Ratified Deloitte & Touche as independent auditor for FY2024: 104.2M for, 276K against, 400K abstain.
- Broker non-votes totaled 22,994,115 on each director election; no other matters voted on.
- Meeting held June 6, 2024; record date April 15, 2024 with 114,912,515 shares outstanding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524157311/0001193125-24-157311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312524157311/d796921d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-157311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer